Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data
Background We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology. Methods Population-based cancer registry data on 72,217 women diagnosed wi...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 2020-09, Vol.123 (5), p.852-859 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 859 |
---|---|
container_issue | 5 |
container_start_page | 852 |
container_title | British journal of cancer |
container_volume | 123 |
creator | Mesa-Eguiagaray, Ines Wild, Sarah H. Rosenberg, Philip S. Bird, Sheila M. Brewster, David H. Hall, Peter S. Cameron, David A. Morrison, David Figueroa, Jonine D. |
description | Background
We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology.
Methods
Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether significant differences were observed in incidence trends by ER status.
Results
Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the 1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960–1986 had lower IRR for ER− tumours.
Conclusions
Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes. |
doi_str_mv | 10.1038/s41416-020-0938-z |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2475028341</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475028341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-1ddbc7867f48f4677602d604aed8673dd2db4ce909ac5b77933122b0cfaf66aa3</originalsourceid><addsrcrecordid>eNqNkkuLFDEQxxtR3HH1A3iRgBdBWvPqTtqDIOMTFjyo55BO0rNZupM2SSu9H8TPa42zOz5AMZdUqn5VVFX-VXWf4CcEM_k0c8JJW2OKa9wxWV_eqDakYbQmkoqb1QZjLCBC8Ul1J-cLeHZYitvVCaMNHMY31beXPhcfTEHFTXNMekQluWAz8gH1yelckNHBuAQO460DEw0pToh0nUAlIopJi_oVTXF0Zhl1Qnnpyzq7_AxpNMcZfMXHUPc6O4tyWeyK4oA-mFiKz-fX5ZPbQStpRVYXfbe6Negxu3tX92n16fWrj9u39dn7N--2L85qwztZamJtb4RsxcDlwFshWkxti7l2FpzMWmp7blyHO22aXoiOMUJpj82gh7bVmp1Wzw9156WfnDUuFFiBmpOfdFpV1F79Hgn-XO3iFyV4C0ukUODRVYEUPy8uFzX5bNw46uDikhXlpKGdZAwD-vAP9CIuKcB4QIkGU8k4-TfFOiIbwlqgyIEyKeac3HBsmWC114Y6aEOBNtReG-oSch78Ousx41oMAMgD8NX1ccjG7z_7iIF6Gk5IxxqwMNn68uNbt3EJBVIf_38q0PRAZyDCzqWfM_69_e_ibeca</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2439185136</pqid></control><display><type>article</type><title>Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><creator>Mesa-Eguiagaray, Ines ; Wild, Sarah H. ; Rosenberg, Philip S. ; Bird, Sheila M. ; Brewster, David H. ; Hall, Peter S. ; Cameron, David A. ; Morrison, David ; Figueroa, Jonine D.</creator><creatorcontrib>Mesa-Eguiagaray, Ines ; Wild, Sarah H. ; Rosenberg, Philip S. ; Bird, Sheila M. ; Brewster, David H. ; Hall, Peter S. ; Cameron, David A. ; Morrison, David ; Figueroa, Jonine D.</creatorcontrib><description>Background
We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology.
Methods
Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether significant differences were observed in incidence trends by ER status.
Results
Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the 1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960–1986 had lower IRR for ER− tumours.
Conclusions
Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-020-0938-z</identifier><identifier>PMID: 32555534</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1857 ; 692/4028/67/2324 ; Age ; Age Factors ; Aged ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Breast Neoplasms - epidemiology ; Breast Neoplasms - metabolism ; Cancer Research ; Cohort Studies ; Drug Resistance ; Epidemiology ; Female ; Humans ; Incidence ; Life Sciences & Biomedicine ; Middle Aged ; Molecular Medicine ; Oncology ; Population studies ; Population-based studies ; Public health ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Registries ; Regression analysis ; Science & Technology ; Scotland - epidemiology ; Trends ; Tumors</subject><ispartof>British journal of cancer, 2020-09, Vol.123 (5), p.852-859</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>32</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000541193500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c498t-1ddbc7867f48f4677602d604aed8673dd2db4ce909ac5b77933122b0cfaf66aa3</citedby><cites>FETCH-LOGICAL-c498t-1ddbc7867f48f4677602d604aed8673dd2db4ce909ac5b77933122b0cfaf66aa3</cites><orcidid>0000-0001-6015-7841 ; 0000-0002-5346-5608 ; 0000-0002-5100-623X ; 0000-0002-2717-7979</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463252/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463252/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,28255,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32555534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mesa-Eguiagaray, Ines</creatorcontrib><creatorcontrib>Wild, Sarah H.</creatorcontrib><creatorcontrib>Rosenberg, Philip S.</creatorcontrib><creatorcontrib>Bird, Sheila M.</creatorcontrib><creatorcontrib>Brewster, David H.</creatorcontrib><creatorcontrib>Hall, Peter S.</creatorcontrib><creatorcontrib>Cameron, David A.</creatorcontrib><creatorcontrib>Morrison, David</creatorcontrib><creatorcontrib>Figueroa, Jonine D.</creatorcontrib><title>Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>BRIT J CANCER</addtitle><addtitle>Br J Cancer</addtitle><description>Background
We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology.
Methods
Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether significant differences were observed in incidence trends by ER status.
Results
Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the 1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960–1986 had lower IRR for ER− tumours.
Conclusions
Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes.</description><subject>631/67/1857</subject><subject>692/4028/67/2324</subject><subject>Age</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cancer Research</subject><subject>Cohort Studies</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Life Sciences & Biomedicine</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Public health</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Registries</subject><subject>Regression analysis</subject><subject>Science & Technology</subject><subject>Scotland - epidemiology</subject><subject>Trends</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkkuLFDEQxxtR3HH1A3iRgBdBWvPqTtqDIOMTFjyo55BO0rNZupM2SSu9H8TPa42zOz5AMZdUqn5VVFX-VXWf4CcEM_k0c8JJW2OKa9wxWV_eqDakYbQmkoqb1QZjLCBC8Ul1J-cLeHZYitvVCaMNHMY31beXPhcfTEHFTXNMekQluWAz8gH1yelckNHBuAQO460DEw0pToh0nUAlIopJi_oVTXF0Zhl1Qnnpyzq7_AxpNMcZfMXHUPc6O4tyWeyK4oA-mFiKz-fX5ZPbQStpRVYXfbe6Negxu3tX92n16fWrj9u39dn7N--2L85qwztZamJtb4RsxcDlwFshWkxti7l2FpzMWmp7blyHO22aXoiOMUJpj82gh7bVmp1Wzw9156WfnDUuFFiBmpOfdFpV1F79Hgn-XO3iFyV4C0ukUODRVYEUPy8uFzX5bNw46uDikhXlpKGdZAwD-vAP9CIuKcB4QIkGU8k4-TfFOiIbwlqgyIEyKeac3HBsmWC114Y6aEOBNtReG-oSch78Ousx41oMAMgD8NX1ccjG7z_7iIF6Gk5IxxqwMNn68uNbt3EJBVIf_38q0PRAZyDCzqWfM_69_e_ibeca</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Mesa-Eguiagaray, Ines</creator><creator>Wild, Sarah H.</creator><creator>Rosenberg, Philip S.</creator><creator>Bird, Sheila M.</creator><creator>Brewster, David H.</creator><creator>Hall, Peter S.</creator><creator>Cameron, David A.</creator><creator>Morrison, David</creator><creator>Figueroa, Jonine D.</creator><general>Nature Publishing Group UK</general><general>Springer Nature</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6015-7841</orcidid><orcidid>https://orcid.org/0000-0002-5346-5608</orcidid><orcidid>https://orcid.org/0000-0002-5100-623X</orcidid><orcidid>https://orcid.org/0000-0002-2717-7979</orcidid></search><sort><creationdate>20200901</creationdate><title>Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data</title><author>Mesa-Eguiagaray, Ines ; Wild, Sarah H. ; Rosenberg, Philip S. ; Bird, Sheila M. ; Brewster, David H. ; Hall, Peter S. ; Cameron, David A. ; Morrison, David ; Figueroa, Jonine D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-1ddbc7867f48f4677602d604aed8673dd2db4ce909ac5b77933122b0cfaf66aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/67/1857</topic><topic>692/4028/67/2324</topic><topic>Age</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cancer Research</topic><topic>Cohort Studies</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Life Sciences & Biomedicine</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Public health</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Registries</topic><topic>Regression analysis</topic><topic>Science & Technology</topic><topic>Scotland - epidemiology</topic><topic>Trends</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mesa-Eguiagaray, Ines</creatorcontrib><creatorcontrib>Wild, Sarah H.</creatorcontrib><creatorcontrib>Rosenberg, Philip S.</creatorcontrib><creatorcontrib>Bird, Sheila M.</creatorcontrib><creatorcontrib>Brewster, David H.</creatorcontrib><creatorcontrib>Hall, Peter S.</creatorcontrib><creatorcontrib>Cameron, David A.</creatorcontrib><creatorcontrib>Morrison, David</creatorcontrib><creatorcontrib>Figueroa, Jonine D.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mesa-Eguiagaray, Ines</au><au>Wild, Sarah H.</au><au>Rosenberg, Philip S.</au><au>Bird, Sheila M.</au><au>Brewster, David H.</au><au>Hall, Peter S.</au><au>Cameron, David A.</au><au>Morrison, David</au><au>Figueroa, Jonine D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><stitle>BRIT J CANCER</stitle><addtitle>Br J Cancer</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>123</volume><issue>5</issue><spage>852</spage><epage>859</epage><pages>852-859</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background
We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology.
Methods
Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether significant differences were observed in incidence trends by ER status.
Results
Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the 1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960–1986 had lower IRR for ER− tumours.
Conclusions
Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32555534</pmid><doi>10.1038/s41416-020-0938-z</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6015-7841</orcidid><orcidid>https://orcid.org/0000-0002-5346-5608</orcidid><orcidid>https://orcid.org/0000-0002-5100-623X</orcidid><orcidid>https://orcid.org/0000-0002-2717-7979</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 2020-09, Vol.123 (5), p.852-859 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_proquest_journals_2475028341 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central |
subjects | 631/67/1857 692/4028/67/2324 Age Age Factors Aged Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - epidemiology Breast Neoplasms - metabolism Cancer Research Cohort Studies Drug Resistance Epidemiology Female Humans Incidence Life Sciences & Biomedicine Middle Aged Molecular Medicine Oncology Population studies Population-based studies Public health Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Registries Regression analysis Science & Technology Scotland - epidemiology Trends Tumors |
title | Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T06%3A43%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinct%20temporal%20trends%20in%20breast%20cancer%20incidence%20from%201997%20to%202016%20by%20molecular%20subtypes:%20a%20population-based%20study%20of%20Scottish%20cancer%20registry%20data&rft.jtitle=British%20journal%20of%20cancer&rft.au=Mesa-Eguiagaray,%20Ines&rft.date=2020-09-01&rft.volume=123&rft.issue=5&rft.spage=852&rft.epage=859&rft.pages=852-859&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-020-0938-z&rft_dat=%3Cproquest_pubme%3E2475028341%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2439185136&rft_id=info:pmid/32555534&rfr_iscdi=true |